Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zolbetuximab in Japanese subjects with advanced gastric/GEJ cancer
NCT03528629Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Jun 2018
- Primary completion
- Jun 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of zolbetuximab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Astellas Pharma. Primary endpoints: Dose Limiting Toxicities, Adverse Events up to 16 months and 2 more. Started Jun 2018; status: completed.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03528629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03528629.